Streetbeat News

Regulatory

NCNA

NuCana presented final data from its Phase 2 Nutide:701 study at the ESMO Congress. The study focused on NUC-7738 in combination with Pembrolizumab for patients with metastatic melanoma who were refractory to or had relapsed on prior PD-1 inhibitor therapy.

Portfolio Pulse from Benzinga Newsdesk

September 16, 2024 | 8:38 am

INCY

Incyte has unveiled promising results for its CDK2 inhibitor, INCB123667, in treating advanced solid tumors, including ovarian cancer. The data supports a pivotal trial in ovarian cancer set for 2025 and plans for combination treatments.

Portfolio Pulse from Benzinga Newsdesk

September 16, 2024 | 7:58 am

EL

Estée Lauder has advised its stockholders to reject TRC Capital's unsolicited mini-tender offer to purchase 1,500,000 shares at $83.65 per share, which is below the current market price. The company emphasizes that TRC's offer is not endorsed and highlights the risks associated with mini-tender offers.

Portfolio Pulse from Benzinga Newsdesk

September 16, 2024 | 7:47 am

PEN

Penumbra, Inc. has secured CE Mark in Europe for its latest thrombectomy technologies, Lightning Flash 2.0 and Lightning Bolt 7, enhancing its position in the vascular treatment market.

Portfolio Pulse from Benzinga Newsdesk

September 16, 2024 | 7:06 am

JNJ

Johnson & Johnson announced new data from the Phase 2b SunRISe-1 study, highlighting the safety and efficacy of TAR-200 for treating BCG-unresponsive, high-risk non-muscle-invasive bladder cancer. The findings were presented at the ESMO 2024 Congress.

Portfolio Pulse from Benzinga Newsdesk

September 16, 2024 | 6:59 am

ESALF

MRK

Merck and Eisai's Phase 3 LEAP-012 trial shows that the combination of KEYTRUDA and LENVIMA with TACE reduces the risk of disease progression or death by 34% in advanced liver cancer patients compared to TACE alone. These results were presented at the European Society for Medical Oncology Congress 2024.

Portfolio Pulse from Benzinga Newsdesk

September 16, 2024 | 6:36 am

MRK

Merck's KEYTRUDA, combined with trastuzumab and chemotherapy, shows significant survival benefits in advanced gastric cancer patients, as per the KEYNOTE-811 study. The results were presented at the ESMO Congress 2024 and published in the New England Journal of Medicine.

Portfolio Pulse from Benzinga Newsdesk

September 16, 2024 | 6:26 am

TSLA

Russia has threatened to turn Kyiv into a 'giant melted spot' if Ukraine uses Western long-range missiles against Russia. This warning comes amid discussions by the U.S. and U.K. to allow Ukraine to use such weapons. The situation raises concerns of a potential military confrontation between Russia and the West.

Portfolio Pulse from Benzinga Neuro

September 16, 2024 | 2:37 am

AAPL

EA

INTC

MSFT

NFLX

QCOM

RBLX

The tech sector faces challenges despite AI buzz, with gaming giants like EA, Roblox, and Microsoft facing accusations of deceiving players. Apple launched the iPhone 16, and Netflix's gaming catalog hit 210M downloads. Qualcomm considers acquiring Intel segments, and Microsoft plans a cybersecurity summit after layoffs.

Portfolio Pulse from Lekha Gupta

September 15, 2024 | 8:03 pm

JPM

MSTR

The crypto world saw major developments, including Jamie Dimon's evolving stance on Bitcoin, the Trump family's DeFi project, and potential election impacts on Bitcoin prices. JPMorgan now holds Bitcoin ETFs, and a Trump victory could push Bitcoin to $90K.

Portfolio Pulse from Benzinga Neuro

September 15, 2024 | 12:04 pm